Complete Omics
Complete Omics Inc. is a leader in clinical proteomics and multi-omics molecular diagnostics, dedicated to advancing personalized medicine through innovative multi-omics platforms and clinical applications. The company has established several robust patented and proprietary platforms, including Deep-Seq for genomics, MetaBoost for metabolomics, Valid-NEO for neoantigen detection, and DEEPER-Seq for ultra-rare mutation calling, supporting research and clinical diagnostics. With a strong focus on clinical impact, they have achieved milestones such as obtaining California Clinical Laboratory License, CLIA and CAP certifications, and forming strategic partnerships to revolutionize disease research and treatment. Their mission is to enable clinical advancements and improve patient outcomes through cutting-edge omics technologies.
Industries
Nr. of Employees
small (1-50)
Complete Omics
Patents
Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample
US-12540946-B2
View Details
Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample
US-12540946-B2
View DetailsProducts
Patented method for neoantigen analysis enabling direct cell-surface quantification
An issued U.S. patent covering an analytical method and system for direct detection and absolute quantification of neoantigens presented on cell surfaces from low-input clinical samples, intended to support companion-diagnostic and translational workflows.
Targeted NGS architecture for low-input and damaged samples
Targeted NGS approach employing barcoded single-strand library preparation and dual-RNA-probe capture to improve recovery and sensitivity for ultra-rare variant detection in FFPE, plasma, ancient, or otherwise degraded clinical samples.
Multiple Myeloma
An oncology medical testing service integrating proteomic, metabolic, and molecular architectures for multiple myeloma diagnostics and monitoring.
Multiple Myeloma Test
Quick and accurate test for multiple myelomas.
Prostate Cancer
An advanced oncology testing service providing prostate cancer risk assessment beyond conventional PSA testing using integrated multi-omics architecture.
Prostate Cancer Screening
Prostate cancer diagnostics and stratifications.
Patented method for neoantigen analysis enabling direct cell-surface quantification
An issued U.S. patent covering an analytical method and system for direct detection and absolute quantification of neoantigens presented on cell surfaces from low-input clinical samples, intended to support companion-diagnostic and translational workflows.
Targeted NGS architecture for low-input and damaged samples
Targeted NGS approach employing barcoded single-strand library preparation and dual-RNA-probe capture to improve recovery and sensitivity for ultra-rare variant detection in FFPE, plasma, ancient, or otherwise degraded clinical samples.
Multiple Myeloma
An oncology medical testing service integrating proteomic, metabolic, and molecular architectures for multiple myeloma diagnostics and monitoring.
Multiple Myeloma Test
Quick and accurate test for multiple myelomas.
Prostate Cancer
An advanced oncology testing service providing prostate cancer risk assessment beyond conventional PSA testing using integrated multi-omics architecture.
Prostate Cancer Screening
Prostate cancer diagnostics and stratifications.
Services
Laboratory-based clinical testing combining proteomics, genomics, and metabolomics for disease diagnostics, biomarker measurement, and translational research reporting.
Direct detection and absolute quantification of tumor neoantigens from limited biopsy material to support personalized immunotherapy development and patient selection.
End-to-end NGS services including targeted capture for damaged or low-input samples, whole-exome/genome sequencing, RNA-Seq, methylation sequencing, ChIP-Seq, and single-cell genomics.
Comprehensive proteomics services including relative and absolute quantitation, PTM mapping, immunopeptidome profiling, host-cell protein analysis, and single-cell proteomics.
Targeted and untargeted small-molecule and lipid profiling using sensitive workflows and chemical derivatization to enhance detection for research and translational applications.
Hands-on training in CLIA/CAP–compliant laboratory workflows, clinical assay development, QA/QC documentation, and audit preparation delivered within an accredited laboratory environment.
Laboratory-based clinical testing combining proteomics, genomics, and metabolomics for disease diagnostics, biomarker measurement, and translational research reporting.
Direct detection and absolute quantification of tumor neoantigens from limited biopsy material to support personalized immunotherapy development and patient selection.
End-to-end NGS services including targeted capture for damaged or low-input samples, whole-exome/genome sequencing, RNA-Seq, methylation sequencing, ChIP-Seq, and single-cell genomics.
Comprehensive proteomics services including relative and absolute quantitation, PTM mapping, immunopeptidome profiling, host-cell protein analysis, and single-cell proteomics.
Targeted and untargeted small-molecule and lipid profiling using sensitive workflows and chemical derivatization to enhance detection for research and translational applications.
Hands-on training in CLIA/CAP–compliant laboratory workflows, clinical assay development, QA/QC documentation, and audit preparation delivered within an accredited laboratory environment.
Expertise Areas
- Clinical proteomics and diagnostics
- Neoantigen discovery and quantitative validation
- Multi-omics integration (genomics, proteomics, metabolomics)
- Targeted and low-input NGS for damaged samples
Key Technologies
- Mass spectrometry–based proteomics
- Immunopeptidomics (mass-spectrometry detection of presented peptides)
- Targeted capture NGS with dual-RNA-probe methodology
- Barcoded single-strand library preparation for low-input DNA
News & Updates
Complete Omics Inc. has obtained the California Clinical Laboratory License, expanding access to clinical proteomics testing.
The company has achieved CLIA and CAP certifications and enrolled in Medicare, demonstrating its commitment to high-quality diagnostic services.
Complete Omics announced a partnership with M20 Genomics to advance single-cell multi-omics for precision medicine.
The company has published groundbreaking research in personalized cancer therapeutics in top scientific journals.
The Valid-NEO® platform received a U.S. patent for its method of neoantigen analysis, a significant milestone in personalized cancer diagnostics.
Complete Omics Inc. has obtained the California Clinical Laboratory License, expanding access to clinical proteomics testing.
The company has achieved CLIA and CAP certifications and enrolled in Medicare, demonstrating its commitment to high-quality diagnostic services.
Complete Omics announced a partnership with M20 Genomics to advance single-cell multi-omics for precision medicine.
The company has published groundbreaking research in personalized cancer therapeutics in top scientific journals.
The Valid-NEO® platform received a U.S. patent for its method of neoantigen analysis, a significant milestone in personalized cancer diagnostics.